IL145397A0 - Compositions and methods for treatment of cancer - Google Patents

Compositions and methods for treatment of cancer

Info

Publication number
IL145397A0
IL145397A0 IL14539701A IL14539701A IL145397A0 IL 145397 A0 IL145397 A0 IL 145397A0 IL 14539701 A IL14539701 A IL 14539701A IL 14539701 A IL14539701 A IL 14539701A IL 145397 A0 IL145397 A0 IL 145397A0
Authority
IL
Israel
Prior art keywords
cancer
compositions
treatment
methods
Prior art date
Application number
IL14539701A
Other languages
English (en)
Original Assignee
Yissum Res Dev Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Res Dev Co filed Critical Yissum Res Dev Co
Priority to IL14539701A priority Critical patent/IL145397A0/xx
Publication of IL145397A0 publication Critical patent/IL145397A0/xx
Priority to PCT/IL2002/000765 priority patent/WO2003022202A2/en
Priority to AU2002341356A priority patent/AU2002341356B2/en
Priority to CA002458543A priority patent/CA2458543A1/en
Priority to IL16081602A priority patent/IL160816A0/xx
Priority to EP02775172A priority patent/EP1424897A4/en
Priority to JP2003526332A priority patent/JP2005508158A/ja
Priority to US10/800,256 priority patent/US7223389B2/en
Priority to US11/561,510 priority patent/US7615209B2/en
Priority to US12/580,722 priority patent/US20100113335A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18161—Methods of inactivation or attenuation
    • C12N2760/18164—Methods of inactivation or attenuation by serial passage

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL14539701A 2001-09-12 2001-09-12 Compositions and methods for treatment of cancer IL145397A0 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
IL14539701A IL145397A0 (en) 2001-09-12 2001-09-12 Compositions and methods for treatment of cancer
PCT/IL2002/000765 WO2003022202A2 (en) 2001-09-12 2002-09-12 Compositions and methods for treatment of cancer
AU2002341356A AU2002341356B2 (en) 2001-09-12 2002-09-12 Compositions and methods for treatment of cancer
CA002458543A CA2458543A1 (en) 2001-09-12 2002-09-12 Compositions and methods for treatment of cancer
IL16081602A IL160816A0 (en) 2001-09-12 2002-09-12 Compositions and methods for treatment of cancer
EP02775172A EP1424897A4 (en) 2001-09-12 2002-09-12 COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER
JP2003526332A JP2005508158A (ja) 2001-09-12 2002-09-12 癌治療のための組成物および方法
US10/800,256 US7223389B2 (en) 2001-09-12 2004-03-11 Compositions and methods for treatment of cancer
US11/561,510 US7615209B2 (en) 2001-09-12 2006-11-20 Compositions of NDV and methods of use thereof for treatment of cancer
US12/580,722 US20100113335A1 (en) 2001-09-12 2009-10-16 Compositions and methods for treatement of cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL14539701A IL145397A0 (en) 2001-09-12 2001-09-12 Compositions and methods for treatment of cancer

Publications (1)

Publication Number Publication Date
IL145397A0 true IL145397A0 (en) 2002-06-30

Family

ID=11075779

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14539701A IL145397A0 (en) 2001-09-12 2001-09-12 Compositions and methods for treatment of cancer

Country Status (7)

Country Link
US (2) US7223389B2 (enExample)
EP (1) EP1424897A4 (enExample)
JP (1) JP2005508158A (enExample)
AU (1) AU2002341356B2 (enExample)
CA (1) CA2458543A1 (enExample)
IL (1) IL145397A0 (enExample)
WO (1) WO2003022202A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2819185A1 (fr) * 2001-01-08 2002-07-12 Oreal Composition cosmetique de texture pateuse a pulverulente et son utilisation en cosmetique
US20070207149A1 (en) * 2004-04-27 2007-09-06 Wellstat Biologics Corporation Cancer treatment using viruses and camptothecins
CA2612949C (en) * 2005-07-14 2015-04-28 Wellstat Biologics Corporation Cancer treatment using viruses, fluoropyrimidines and camptothecins
US20090175826A1 (en) * 2006-06-05 2009-07-09 Elankumaran Subbiah Genetically-engineered newcastle disease virus as an oncolytic agent, and methods of using same
US20100297072A1 (en) * 2009-05-19 2010-11-25 Depinho Ronald A Combinations of Immunostimulatory Agents, Oncolytic Virus, and Additional Anticancer Therapy
EP2327764B1 (en) 2009-11-30 2011-12-28 United Cancer Research Institute New clone of Newcastle disease virus, its manufacture and its application in the medical treatment of cancer
US20120308437A1 (en) * 2009-12-14 2012-12-06 Xiaoqun Zhou Detector Module, a Method for Controlling the Detector Module and a Detection System
RU2482129C2 (ru) * 2010-11-11 2013-05-20 Никита Юрьевич Силко Штамм вируса болезни ньюкасла для создания на его основе кандидатного противоракового препарата и изучения механизмов онколизиса
WO2014011072A1 (ru) * 2012-07-11 2014-01-16 Zabelin Vladimir Arkad Evich Штамм-продуцент вируса болезни ньюкасла ndv/anas crecca/omsk/9/2010, используемый для создания на его основе кандидатного противоракового препарата
WO2015023285A1 (en) * 2013-08-15 2015-02-19 Xia Xueliang James Biomarkers for use in colorectal cancer
RU2562115C1 (ru) * 2014-11-13 2015-09-10 Федеральное государственное автономное образовательное учреждение высшего образования "Новосибирский национальный исследовательский государственный университет"(Новосибирский государственный университет, НГУ) Штамм вируса болезни ньюкасла для изучения онколитических свойств и механизмов онколизиса для создания прототипного противоопухолевого препарата
CN106868130B (zh) * 2014-12-24 2021-03-12 北京丽阳吉诺科技有限公司 用于结肠直肠癌中使用的生物标志物
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
EP3837277A4 (en) 2018-08-17 2022-05-11 Icahn School of Medicine at Mount Sinai RECOMBINANT NEWCASTLE DISEASE VIRUSES AND THEIR USES IN THE PREVENTION OF RSV DISEASE OR HUMAN METAPNEUMOVIRUS INFECTION
CN114774373B (zh) * 2022-04-27 2024-07-05 北京市农林科学院 信鸽新城疫病毒基因工程改造弱毒株及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5215745A (en) * 1988-04-27 1993-06-01 United Cancer Research Institute Method for treating viral diseases with attenuated virus
US5124148A (en) * 1988-04-27 1992-06-23 United Cancer Research Institute Method for treating viral diseases with attenuated virus
US5118502A (en) * 1989-06-20 1992-06-02 The University Of Georgia Research Foundation, Inc. Naturally attenuated newcastle disease vaccine and method of using the same
EP0575491B1 (en) * 1991-03-07 2003-08-13 Virogenetics Corporation Genetically engineered vaccine strain
US5602023A (en) * 1992-03-24 1997-02-11 Csatary; Laszlo K. Pharmaceutical product containing live, stabilized virus for the therapy of viral and malignant diseases and process for preparing the same
ES2310580T3 (es) * 1993-04-30 2009-01-16 Wellstat Biologics Corporation Composiciones purificadas del virus de la enfermedad de newcastle.
EP0770397B1 (en) * 1995-10-18 2004-04-21 Akzo Nobel N.V. Newcastle disease virus combination vaccine
FR2749323B1 (fr) * 1996-06-04 1998-07-10 Pasteur Merieux Serums Vacc Pseudo-particules virales utiles en tant que vecteur de delivrance d'acide nucleique
FR2751225B1 (fr) * 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique aviaire
US20030044384A1 (en) * 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
EP0974660A1 (en) * 1998-06-19 2000-01-26 Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO) Newcastle disease virus infectious clones, vaccines and diagnostic assays
NZ527687A (en) * 2001-05-11 2005-10-28 Wellstat Biolog Corp Formerly Preferential binding of an oncolytic virus such as Newcastle Disease Virus (NDV) to leukocytes compared with erythrocytes used as a therapy for cancer

Also Published As

Publication number Publication date
WO2003022202A9 (en) 2004-04-22
EP1424897A4 (en) 2009-06-17
US20050031642A1 (en) 2005-02-10
CA2458543A1 (en) 2003-03-20
US20100113335A1 (en) 2010-05-06
JP2005508158A (ja) 2005-03-31
EP1424897A2 (en) 2004-06-09
WO2003022202A3 (en) 2004-03-18
US7223389B2 (en) 2007-05-29
WO2003022202A2 (en) 2003-03-20
AU2002341356B2 (en) 2007-11-15

Similar Documents

Publication Publication Date Title
AU6147401A (en) Compositions and methods for the treatment of cancer
EP1390014A4 (en) COMPOSITION AND METHODS FOR TREATING HYPERPLASIA
IL161775A0 (en) Topical compositions and methods for treatment of adverse effects ofionizing radiation
AU2002364364A8 (en) Method of treating apoptosis and compositions thereof
IL161733A0 (en) Methods and compositions for therapeutic use of rna interference
AU2002226069A1 (en) Compositions comprising temozolomide and thalidomide and methods for the treatment of cancer
AU2002328952A1 (en) Irinotecan for treatment of cancer
IL162153A0 (en) Methods and compositions for treatment of central nervous systemdisorders
IL157425A0 (en) Treatment of solid tumours with paramycin derivatives
AU5160201A (en) Compositions comprising natural agents for treatment of cancer
PL352931A1 (en) Compositions and uses of et743 for treating cancer
EP1476067A4 (en) COMPOSITIONS AND METHODS FOR CANCER
EP1463495A4 (en) AGENTS AND METHODS FOR TREATING CANCER
EP1424897A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER
IL158206A0 (en) Compositions and methods for the prevention and treatment of human prostate cancer
IL165839A0 (en) Compounds useful for the treatment of cancer compositions thereof and methods therewith
PL368035A1 (en) Compositions and methods for the treatment of cancer
EP1469769A4 (en) NEW COMPOSITIONS AND METHODS AGAINST CANCER
AU2003219160A1 (en) Methods and compositions for the treatment of cancer
EP1416795A4 (en) COMPOSITIONS AND METHODS OF TREATING DISEASES OF MITOCHONDRIA
GB0124124D0 (en) Methods of treatment
AUPR644301A0 (en) Method and composition for treatment of cancer
AU2002337713A1 (en) Pharmaceutical compositions and methods for treating cancer
IL154354A0 (en) Composition for prophylaxis and treatment of cancer
EP1469870A4 (en) NEW COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER